Taiko Pharmaceutical Co.,Ltd. (TYO:4574)
277.00
-3.00 (-1.07%)
Jul 16, 2025, 3:30 PM JST
Taiko Pharmaceutical Balance Sheet
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Cash & Equivalents | 4,673 | 4,532 | 5,484 | 3,105 | 5,796 | 4,944 | Upgrade |
Short-Term Investments | - | - | - | 400 | 302 | - | Upgrade |
Cash & Short-Term Investments | 4,673 | 4,532 | 5,484 | 3,505 | 6,098 | 4,944 | Upgrade |
Cash Growth | -10.79% | -17.36% | 56.46% | -42.52% | 23.34% | -50.09% | Upgrade |
Receivables | 1,716 | 2,428 | 1,985 | 1,798 | 4,056 | 7,918 | Upgrade |
Inventory | 1,871 | 1,675 | 1,373 | 1,952 | 3,205 | 6,408 | Upgrade |
Other Current Assets | 147 | 126 | 267 | 301 | 424 | 552 | Upgrade |
Total Current Assets | 8,407 | 8,761 | 9,109 | 7,556 | 13,783 | 19,822 | Upgrade |
Property, Plant & Equipment | 3,291 | 3,271 | 3,581 | 6,397 | 7,113 | 9,446 | Upgrade |
Long-Term Investments | 433 | 747 | 526 | 867 | 1,338 | 1,564 | Upgrade |
Other Intangible Assets | 27 | 27 | 1 | 222 | 299 | 319 | Upgrade |
Long-Term Deferred Tax Assets | - | 105 | 1 | 2 | - | 605 | Upgrade |
Other Long-Term Assets | 3 | 3 | 2 | 2 | 2 | 1 | Upgrade |
Total Assets | 12,161 | 12,914 | 13,220 | 15,046 | 22,535 | 31,757 | Upgrade |
Accounts Payable | 891 | 338 | 375 | 274 | 309 | 2,928 | Upgrade |
Accrued Expenses | 38 | 176 | 75 | 23 | 149 | 513 | Upgrade |
Current Portion of Long-Term Debt | 1,206 | 1,206 | 1,206 | 1,039 | 923 | - | Upgrade |
Current Portion of Leases | - | 18 | 27 | 29 | 36 | 31 | Upgrade |
Current Income Taxes Payable | 3 | 728 | 782 | 571 | 1,282 | 3,181 | Upgrade |
Other Current Liabilities | 322 | 389 | 581 | 857 | 1,621 | 834 | Upgrade |
Total Current Liabilities | 2,460 | 2,855 | 3,046 | 2,793 | 4,320 | 7,487 | Upgrade |
Long-Term Debt | 421 | 792 | 1,999 | 2,720 | 3,760 | - | Upgrade |
Long-Term Leases | - | 11 | 22 | 21 | 54 | 63 | Upgrade |
Long-Term Deferred Tax Liabilities | - | 20 | 188 | 125 | 104 | - | Upgrade |
Other Long-Term Liabilities | 614 | 618 | 603 | 685 | 686 | 685 | Upgrade |
Total Liabilities | 4,182 | 4,951 | 6,482 | 7,003 | 9,729 | 8,977 | Upgrade |
Common Stock | 10 | 10 | 2,267 | 1,201 | 1,201 | 1,148 | Upgrade |
Additional Paid-In Capital | 4,997 | 4,997 | 2,689 | 1,642 | 1,648 | 1,516 | Upgrade |
Retained Earnings | 2,819 | 2,526 | 1,628 | 5,239 | 10,134 | 20,509 | Upgrade |
Treasury Stock | -273 | -273 | -300 | -348 | -388 | -480 | Upgrade |
Comprehensive Income & Other | 426 | 703 | 454 | 309 | 211 | 87 | Upgrade |
Shareholders' Equity | 7,979 | 7,963 | 6,738 | 8,043 | 12,806 | 22,780 | Upgrade |
Total Liabilities & Equity | 12,161 | 12,914 | 13,220 | 15,046 | 22,535 | 31,757 | Upgrade |
Total Debt | 1,627 | 2,027 | 3,254 | 3,809 | 4,773 | 94 | Upgrade |
Net Cash (Debt) | 3,046 | 2,505 | 2,230 | -304 | 1,325 | 4,850 | Upgrade |
Net Cash Growth | 30.45% | 12.33% | - | - | -72.68% | -50.66% | Upgrade |
Net Cash Per Share | 60.68 | 49.92 | 47.09 | -6.97 | 30.45 | 111.86 | Upgrade |
Filing Date Shares Outstanding | 50.19 | 50.19 | 50.15 | 43.58 | 43.58 | 43.33 | Upgrade |
Total Common Shares Outstanding | 50.19 | 50.19 | 49.95 | 43.58 | 43.58 | 43.32 | Upgrade |
Working Capital | 5,947 | 5,906 | 6,063 | 4,763 | 9,463 | 12,335 | Upgrade |
Book Value Per Share | 158.96 | 158.65 | 134.90 | 184.57 | 293.84 | 525.90 | Upgrade |
Tangible Book Value | 7,952 | 7,936 | 6,737 | 7,821 | 12,507 | 22,461 | Upgrade |
Tangible Book Value Per Share | 158.43 | 158.11 | 134.88 | 179.48 | 286.98 | 518.54 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.